Top Markets
#1 Black Phoenix Black Phoenix +365.85%
#2 Islamic Coin Islamic Coin +158.20%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +55.15%
#5 Akedo Akedo +34.14%
#6 BasedHype BasedHype +29.84%
#7 Acurast Acurast +29.21%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.11%
#9 Cryptopia Cryptopia +21.42%
#10 GoPlus Security GoPlus Security +20.47%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings, Inc.

AMBS
Classement en actions #41184
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm,... Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine. The company's diagnostic pipeline includes the LymPro test, a blood-based diagnostic designed to detect Alzheimer's disease by analyzing lymphocyte proliferation, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying individuals with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug targeting both Levadopa-Induced Dyskinesia in Parkinson's patients and attention deficit hyperactivity disorders (ADHD). Additionally, they are developing a mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating conditions modeled in animals, such as retinitis pigmentosa and retinal artery occlusion. Amarantus also maintains several specialized platforms: NuroPro, a diagnostic platform dedicated to neurodegenerative diseases with an initial application in Parkinson's; BC-SeraPro, an oncology diagnostic platform specifically for breast cancer; and the PhenoGuard platform, designed for discovering new neurotrophic factors. Beyond these, the company is progressing with Engineered Skin Substitute (ESS), a cell therapy-based product for autologous skin replacement, currently in mid-stage clinical development for severe, life-threatening burns. The company has established a collaborative research and development agreement with both the U.S. Army Institute of Surgical Research and Rutgers University. Established in 2008, Amarantus BioScience Holdings, Inc., which previously operated as Amarantus Bioscience, Inc. until its name change in April 2013, is headquartered in New York, New York.
Prix de l'action
$0.0001
Dernière synchronisation: 2026-08-11
Capitalisation boursière
$36.84K
Changement (1 jour)
0.00%
Changement (1 an)
-66.67%
Pays
US
Échange Amarantus BioScience Holdings, Inc. (AMBS)

Catégorie

Healthcare
EPS pour Amarantus BioScience Holdings, Inc. (AMBS)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Amarantus BioScience Holdings, Inc., l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de Amarantus BioScience Holdings, Inc. de 2026 à 2026
EPS à la fin de chaque année
Année EPS Changez
Pas assez de données pour les dates fournies.
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $13.70 -
BE